CXCL8 and prostate neoplasm: Our demonstration that combined VEGF/IL8 inhibition extends the duration of sensitivity of prostate tumors to enzalutamide in vivo and restores sensitivity of drug-resistant models encourages future evaluation in further experimental models, and potential translation of this discovery to proof-of-concept trials.